Critical importance of in vivo amoxicillin and cefotaxime concentrations for synergy in treatment of experimental Enterococcus faecalis endocarditis.
The synergy between amoxicillin and cefotaxime against two strains of Enterococcus faecalis (JH2-2 and 6370) in vitro and in rabbit endocarditis was investigated. In vitro synergy was obtained only when amoxicillin concentrations were below the MBC and when cefotaxime concentrations were above 1 microg/ml. No synergy was observed in vivo, because of the short period of time during which these pharmacologic requirements were achieved.
Join-Lambert
O
O
Institut National de la Santé et de la Recherche Médicale, Unité 13, Paris, France.
Mainardi
J L
JL
Cuvelier
C
C
Dautrey
S
S
Farinotti
R
R
Fantin
B
B
Carbon
C
C
D000658:Amoxicillin / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000818:Animals; D002439:Cefotaxime / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004357:Drug Synergism; D004359:Drug Therapy, Combination / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004697:Endocarditis, Bacterial / Q000188:drug therapy*; D013293:Enterococcus faecalis / Q000187:drug effects*; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy*; D011817:Rabbits
D000658:Amoxicillin; D002439:Cefotaxime